-+ 0.00%
-+ 0.00%
-+ 0.00%

Summit Therapeutics launches Phase III ivonescimab trial in Stage III lung cancer

PUBT·11/18/2026 11:02:01
Summit Therapeutics launches Phase III ivonescimab trial in Stage III lung cancer
  • Summit Therapeutics launched HARMONi-10, a global Phase III trial comparing ivonescimab with durvalumab as consolidation therapy for unresectable Stage III lung cancer.
  • The study targets patients with non-small cell lung cancer whose disease has not progressed following platinum-based concurrent chemoradiation.
  • Future results will assess whether ivonescimab delays disease progression compared with the current standard of care.
  • Global trial site activations are expected to begin in the fourth quarter of 2026.
  • HARMONi-10 is the sixth company-sponsored Phase III ivonescimab study, extending its development program into earlier-stage disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611180600BIZWIRE_USPR_____20261118_BW004467) on November 18, 2026, and is solely responsible for the information contained therein.